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Problem Identification and Description of
Need


Age-related macular degeneration (AMD) is the leading cause of severe, irreversible
vision loss in the developed world1



Low vision is socially isolating, decreases functioning and quality of life. It is
associated with significant comorbidities including falls and depression15



In 2004, 1.75M Americans have severe AMD in at least one eye, and another 7.3M
with high-risk features. This number is estimated to increase to 3 million by 20201



Risk Factors: Age,3 Caucasian race,2 smoking,5 genetic factors, family history6



Prevalence increases with age, from 4.2% in persons age 43-54 to 46% in persons age
75 or older3





In Maine, 95% white, 38.7% age 50 and older4



In Penobscot County, 16.5% age 65 and older. This percentage is increasing4

The Age-related Eye Disease Studies (AREDS) estimated that of the 8 million
individuals considered high risk for the development of advanced stage AMD in 2003,
300 thousand would have avoided progression to advanced stage disease and any
subsequent vision loss (over a period of 5 years) had they received preventative
AREDS nutritional supplementation8
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Problem Identification and Description of
Need









USPSTF currently has insufficient information to recommend routine
screening for AMD based on visual acuity alone (Grade I
recommendation)
AAO Preferred Practice Patterns recommends yearly fundus exams
and patient self monocular visual acuity and Amsler grid exams in
individuals with early stage disease or positive family history13
The AREDS and AREDS2 trials demonstrated a 10% - 30% reduction
in progression to advanced disease in individuals with intermediate
AMD (one or more drusen >125µm) supplemented with
antioxidants and carotenoids11, 12
Fundus examination is non-invasive and represents minimal risk to
the patient
Taken together, targeted questions, cursory fundus exam and
Amsler grid testing now meets the criteria for a good screening test
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Public health costs


Cost to Patient
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Cost to Medical System



$2,700/QALY* for monthly
Bevacizumab9



$574 million in direct medical costs
in 20047



$63,000/QALY for monthly
Ranibizumab9





$14,000/QALY for implantable
miniature telescope10

Wholesale prices of anti-VEGF
intravitreal injections $50-$1950 per
dose9



Compare to $60 - $120 for AREDS
nutritional supplements (1 year
supply)

*Quality adjusted life-year

Community perspective and
support for project
“AMD is a disease with insidious onset and can be
unilateral… so patients may not notice a change
in vision until the disease is in the more advanced
stages. The most important things [PCPs] can do is
identify and assess patients with risk factors, and
make timely referrals.”
- M.J., M.D., local ophthalmolgist*

“Not everyone receives routine eye exams
because [vision insurance] is often not covered by
employers. Most of us ask about vision changes as
part of the review of systems, but I don’t think
specific screening questions and fundus exams are
a big enough part of what we’re doing. It would
be interesting to gauge residents’ exposure to and
proficiency with the fundus exam.”
-

“I live half an hour from the clinic. I’ve never
needed glasses so I have no reason to see an eye
doctor. I only see the [PCP] when I’m sick. A
couple of my friends have AMD that were caught
when it was already bad, and the thought of
going blind is real scary.”

Jessica Bloom-Foster, M.D., Center for Family
Medicine Preceptor

- Margaret Gauthier, Center for Family Medicine
patient
*Interviewee consented to interview but declined publication of identifying information. Names are on file in
the University of Vermont College of Medicine Family Medicine Department
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Intervention and methodology
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In a 2009 prospective longitudinal study, 98% of 2nd year medical students reported self-rated
competency in optic disc visualization. However, expert audits of 3rd and 4th year student
charts demonstrated that 43% of post-family medicine and 91% of post-internal medicine
workups reflected inadequate eye evaluations. The authors concluded that skills performance
decayed when not habitually practiced.14 These results can almost certainly be extrapolated
to primary care residency training and beyond.


Patient



Primary Care Provider



Assess patient knowledge of AMD risk factors,
early signs and symptoms, and care
management using a 14 point questionnaire



Assess provider knowledge of AMD risk
factors, early signs and symptoms, and
care management using a 10 point
questionnaire



Questionnaire distributed at check-in by front
office staff to all adult (18+) patients at CFM



SurveyMonkey distributed to CFM
providers and three regional primary care
practices



Education with a brief, informative, looping
slideshow in the waiting room highlighting the
epidemiology, risks, and symptoms of AMD



Assess provider comfort with fundus
examination and Amsler grid testing



Formation of an informative flyer for each
examination room highlighting the
epidemiology, risks, and symptoms of
AMD, and care management steps



Creation of an informative flyer for each
examination room highlighting the
epidemiology, risks, and symptoms of AMD

Results – patient (n=46)
Did you know...?
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Please rate your knowledge of early signs
and symptoms of AMD

Do you...?

AMD most commonly
affects the elderly

Know what treatment
options are available for
AMD

Advanced AMD can be
prevented or slowed if
detected early

Wish you knew more about
AMD

AMD can run in the family

Currently have AMD in one
or both eyes

Smokers are at higher risk
for AMD

Have a family member with
or who had AMD

AMD most commonly
affects white individuals

Know what AMD is

adequate
16%

none
34%
wish I knew
more
32%

0

Vision loss from AMD begins
in the center of vision

expert
2%

20

40

60

80

100

Please rate you knowledge of risk factors
for developing AMD
expert
0%

Percent of responses
yes

AMD is leading cause of
irreversible central blindness
in the US
0

20

40

60

80

Percent of responses
yes

no

100

no

poor
16%

adequate
18%

wish I knew
more
32%

none
36%

poor
14%

Results – primary care providers (n=23)
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Please check one:
Percent of responses

50

Completely disagree

Somewhat disagree

Neutral

Somewhat agree

Completely agree

40
30
20
10
0
I routinely ask patients about vision at well
visits

I can confidently perform the fundus
exam and identify drusen

I can confidently perform and interpret
the Amsler grid test

I can counsel patients on visual aids and
low-vision behavioral modifications

Please rate your knowledge of:
Percent of responses

70
60

None

Poor

Wish I knew more

Adequate

Expert

50
40
30
20
10
0
AMD risk factors

Early signs and symptoms of
AMD

Guidelines for referral to
ophthalmology for AMD

AMD treatment options and Low-vision rehab services
adverse effects
and resources

Low-vision community
support resources

Evaluation of effectiveness and
limitations


Only 18% of patients reported adequate or
expert knowledge of early signs and
symptoms. 50% reported poor to no
knowledge.



Similarly, 18% of patients reported adequate
knowledge of risk factors. 50% reported poor
to no knowledge.



64% of patients did not know what AMD was,
but 74% wish they knew more about the
disease.



Patients with AMD in one or both eyes, or who
have family members with AMD, were more
likely to be knowledgeable of signs,
symptoms and risk factors.



This data suggests that knowledge of AMD risk
factors, signs and symptoms are lacking in the
general adult population. However, the vast
majority desire to know more



The findings suggest a need and desire for
timely education and risk identification by
primary care providers



Although not directly shown by our data, it is
reasonable to infer that patients lack
adequate knowledge of the disease until
they are diagnosed with AMD. An
association may be revealed if the survey
were extended to capture more patients with
and without the diagnosis



Organization and order of survey questions
may have inadvertently tipped patients and
altered responses with respect to knowledge
level



We propose to evaluate the effectiveness of
interventions by readministering questionnaire
to same patients after they have reviewed
the handout
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Evaluation of effectiveness and
limitations


70% of providers routinely ask about visits at
Well-visits. However, 43% of providers
somewhat or completely disagree that they
can comfortably perform a fundus exam



52% of providers somewhat or completely
disagree that they can comfortably perform
and interpret the Amsler grid test



Approximately 40% of providers wish they
knew more about the risk factors for AMD,
while only 34% considered themselves to have
adequate or expert knowledge of the risk
factors



43% of providers wish they knew more of early
signs and symptoms of AMD, while 53%
considered themselves adequate or expert



39% of providers had poor to no knowledge of
the available low-vision rehab services, and
43% had poor to no knowledge of the
available low-vision community support
resources



While 70% of providers report routinely asking
about vision during well-visits, depth of
questioning and line of questioning looking
specifically for AMD is unclear



The PCP survey was announced and residents
and faculty were asked to participate during
a clinic team huddle. While clearly stated
that responses were confidential and used for
internal analysis only, a significant Hawthorne
effect/observation bias may exist



We propose to evaluate the effectiveness of
interventions by readministering questionnaires
after review of PCP care management
handout.


Further evaluate with formal assessment
of interviewing and physical exam skills,
and professional chart audits
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Recommendations for future
interventions and projects
For at-risk patients, PCPs play a crucial role in recognizing functional and
anatomic symptoms, issuing timely referrals, and overseeing risk factor
modification. In patients with uncorrectable vision loss, the PCP’s role shifts
to optimizing quality of life and facilitating low-vision rehabilitation.15
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Table 1.15
How did you see 10 years ago?
How is your reading?



Creation of an automated page in the EMR for the guidance of
primary care provider screening questions



It is not uncommon for people with even severe monocular vision loss
to be unaware of their condition if they have good vision in the fellow
eye - simply asking “Any changes in vision?” may not be enough. Ask
all adult smokers and/or those with a family history specific vision
questions (Table 1)



Educate all adult smokers and/or those with a family history of AMD
about the early signs and symptoms of AMD

Have you noticed any dark areas,
blurry areas, or whiteout?



Larger trials could provide more insight into patient and provider
knowledge of AMD that encompasses a more diverse population

When did you first notice changes in
your vision?



We recommend formal workshops that encompass funduscopic
examination, referral guidelines, treatment options, and follow-up for
AMD to all primary care providers using a reiterative training model

How has your vision changed in the
last 3 months?

What can’t you do now that you
were previously able to?
Have you noticed that straight lines
have become distorted or wavy?

References
1.

Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the
United States. Arch Ophthalmol 2004;122:564-72

2.

Jampol LM, Tielsch J. Race, macular degeneration, and the Macular Photocoagulation Study. Arch
Ophthalmol 1992;110:1699-700

3.

Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy:
The Beaver Dam Eye Study. Ophthalmology 2002;109:1767-79

4.

2010, 2014 Maine Census Data, retrieved from website www.census.gov

5.

Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of
pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and
choroidal neovascularisation. Br J Ophthalmol 2006;90:75-80

6.

Hammond CJ, Webster AR, Snieder H, et al. Genetic influence on early age-related maculopathy: a
twin study. Ophthalmology 2002;109:730-6

7.

Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United
States. Arch Ophthalmol 2006;124:1754-60

8.

Bressler NM, Bressler SB, Congdon NG, et al. Age-Related Eye Disease Study Research Group. Potential
public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol
2003;121:1621-4

9.

Nwanze CC, Akinwale A, Adelman RA. Bevacizumab vs. ranibizumab in preserving or improving vision in
patients with wet, age-related macular degeneration: a cost-effectiveness review. Clin Med Insights
Ther 2012;4:29-38

10.

Brown GC, Brown MM, Lieske HB, et al. Comparative effectiveness and cost-effectiveness of the
implantable miniature telescope. Ophthalmology 2011;118:1834-43

9a

References
11.

Chew EY, Clemons TE, Agron E et al. Ten-year follow-up of age-related macular degeneration in the
age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014 Mar;132(3):272-7

12.

Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for
age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical
trial. JAMA. 2013 May 15;309(19):2005-15

13.

AAO Retina/Vitreous PPP Panel. Age-Related Macular Degeneration PPP - Updated 2015. Retrieved
from website www.aao.org

14.

Mottow-Lippa L, Boker JR, Stephens F. A prospective study of the longitudinal effects of an embedded
specialty curriculum on physical examination skills using an ophthalmology model. Acad Med. 2009
Nov;84(11):1622-30

15.

Marra KV, Wagley S, Kuperwaser MC, Campo R, Arroyo JG. Care of Older Adults:Role of Primary Care
Physicians in the Treatment of Cataracts and Macular Degeneration. J Am Geriatr Soc. 2016
Feb;64(2):369-77

9b

